Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Two Doses of Avaxim 80U Pediatric in Children and Adolescents in China
2015-003190-14Phase 4
- Sponsor
- Sanofi
- Start
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Avaxim Junior in hepatitis A (HAV), sponsored by Sanofi. Primary endpoint: Unsolicited systemic adverse events within 30 minutes after vaccination.
02
Drugs
Avaxim Junior
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on 2015-003190-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003190-14.